Nasdaq · CIK 0001512762
CHRS Coherus Oncology, Inc.
Insider trading from SEC Form 4. Last filing Jun 13, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at Coherus Oncology, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 43Moderate | Mats Wahlstrom director sell | $74k 99,988 shares | -100% | - |
Transactions
The last 21 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2025 | Charles W. Newton director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Jun 12, 2025 | Georgia Erbez director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Jun 12, 2025 | Rita A Karachun director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Jun 12, 2025 | Michael Lee Ryan director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Jun 12, 2025 | Mats Wahlstrom director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Jun 12, 2025 | Lee Nisley Newcomer director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Jun 12, 2025 | Jill O'Donnell-Tormey director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| Jun 12, 2025 | Ali J. Satvat director | AGrant or award Stock Option (Right to Buy)derivative | +112,000 | $0.00 | $0 | 112,000 | Jun 13, 2025 |
| May 23, 2025 | Mats Wahlstrom director | SOpen-market sale Common Stockindirect: Leonard Capital, LLC | -99,988 | $0.74 | $74k | 0 | May 28, 2025 |
| May 7, 2025 | Bryan J McMichael Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | May 9, 2025 |
| May 7, 2025 | Dennis M Lanfear President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +375,000 | $0.00 | $0 | 375,000 | May 9, 2025 |
| Jan 20, 2025 | Dennis M Lanfear President & CEO | FTax withholding Common Stock | -11,810 | $1.39 | $16k | 685,074 | Jan 22, 2025 |
| Jan 20, 2025 | Paul Reider Chief Commercial Officer | FTax withholding Common Stock | -4,858 | $1.39 | $6,753 | 82,069 | Jan 22, 2025 |
| Jan 20, 2025 | Bryan J McMichael Chief Financial Officer | FTax withholding Common Stock | -1,711 | $1.39 | $2,378 | 22,951 | Jan 22, 2025 |
| Jan 10, 2025 | Dennis M Lanfear President & CEO | AGrant or award Stock Option (Right to Buy)derivative | +575,000 | $0.00 | $0 | 575,000 | Jan 14, 2025 |
| Jan 7, 2025 | Bryan J McMichael Chief Financial Officer | FTax withholding Common Stock | -1,711 | $1.57 | $2,686 | 24,662 | Jan 10, 2025 |
| Jan 4, 2025 | Paul Reider Chief Commercial Officer | FTax withholding Common Stock | -2,277 | $1.66 | $3,780 | 86,927 | Jan 7, 2025 |
| Jan 4, 2025 | Dennis M Lanfear President & CEO | FTax withholding Common Stock | -11,810 | $1.66 | $20k | 696,884 | Jan 7, 2025 |
| Jan 3, 2025 | Bryan J McMichael Chief Financial Officer | AGrant or award Stock Option (Right to Buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Jan 7, 2025 |
| Jan 3, 2025 | Paul Reider Chief Commercial Officer | AGrant or award Stock Option (Right to Buy)derivative | +160,000 | $0.00 | $0 | 160,000 | Jan 7, 2025 |
| Dec 13, 2024 | Paul Reider Chief Commercial Officer | FTax withholding Common Stock | -2,073 | $1.61 | $3,338 | 89,204 | Dec 17, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Georgia Erbezcfo, officer, director
- Rita A Karachundirector
- Dennis M LanfearPresident & CEO
- Bryan J McMichaelChief Financial Officer
- Lee Nisley Newcomerdirector
- Charles W. Newtondirector, cfo, officer
- Jill O'Donnell-Tormeydirector
- Paul ReiderChief Commercial Officer
- Michael Lee Ryandirector
- Ali J. Satvatdirector
- Mats Wahlstromdirector, owner
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.